SLC5A2 and diabetes mellitus: This systematic review is performed to consolidate the evidence of sodium-glucose cotransport-2 (SGLT2) inhibitors to reduce cardiovascular and renal complications and adverse effects in diabetes mellitus from 22 randomized control trials and observational studies.